Non-Invasive Prenatal Analysis for RhD

◄ Back to Transfusion News

The Red Cell Reference laboratory now offers Non-Invasive Prenatal Analysis (NIPA) for blood group genotyping to determine the RhD status of the fetus.

The NIPA service is available to all RhD negative pregnant women who fall into one of the following three categories:

  1. Alloimmunised (maternal anti-D)
  2. Following severe fetomaternal haemorrhage during pregnancy, or intrauterine fetal death
  3. A relative contraindication to routine antenatal Anti-D prophylaxis, where the fetal RhD genotype result will guide anti-D prophylaxis decisions e.g. prior allergic reaction to RhD-Ig, or cultural/religious beliefs.

NIPA testing can be performed from 12 weeks gestation and will require two additional EDTA blood samples to be collected for testing. Samples must arrive at the Blood Service within 72 hours of collection.

This new service will aid in assessing pregnancies at risk of Haemolytic Disease of the Fetus and Newborn (HDFN) and help guide clinical management.

 

For more information please see the NIPA for Blood Group Genotyping Information Sheet.